Hidradenitis Suppurativa and Maternal and Offspring Outcomes
JAMA Dermatology · 01.12.2024 · 160 (12) · 1297
DOI: 10.1001/jamadermatol.2024.3584 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Dermatology, erschienen am 01.12.2024. Verfasst von Kaiyang Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Pregnancy Outcome, Diabetes, Gestational, Hospitalization. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Hidradenitis suppurativa (HS) is associated with morbidity in persons of reproductive age, but the effect on maternal and offspring outcomes is understudied.
Objective
To determine the association of HS with pregnancy outcomes and maternal and child morbidity in the long term. Design, Setting, and Participants This population-based longitudinal cohort study with up to 16 years of follow-up took place between 2006 and 2022 in Quebec, Canada. . Exposure Maternal HS. Main Outcomes and Measures Outcomes included hypertensive disorders of pregnancy, gestational diabetes, and other birth outcomes as well as the long-term risk of hospitalization up to 16 years after delivery. The study used adjusted log-binomial and Cox proportional hazards regression models to estimate the association between maternal HS and pregnancy outcomes or hospitalization following pregnancy. Outcomes in both mothers and offspring were assessed.
Results
There were 1 324 488 deliveries during the study, including 1332 (0.1%) among mothers with HS. Compared with patients without HS, patients with HS had a greater risk of hypertensive disorders of pregnancy (risk ratio [RR], 1.55 [95% CI, 1.29-1.87]), gestational diabetes (RR, 1.61 [95% CI, 1.40-1.85]), and severe maternal morbidity (RR, 1.38 [95% CI, 1.03-1.84]). In neonates, maternal HS was associated with risk of preterm birth (RR, 1.28 [95% CI, 1.07-1.53]) and birth defects (RR, 1.29 [95% CI, 1.07-1.56]). In the long term, HS was associated with 2.29 times the risk of maternal hospitalization (95% CI, 2.07-2.55) and 1.31 times the risk of childhood hospitalization (95% CI, 1.18-1.45), including hospitalization for respiratory, metabolic, psychiatric, and immune-related morbidity over time. Conclusions and Relevance This cohort study found that HS is associated with adverse maternal and offspring outcomes in the peripartum period and in the long term. Early detection and management of HS may help mitigate these outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada.
- Division of Dermatology, Department of Medicine, Women's College Hospital, University of Toronto, Toronto, Ontario, Canada.
- Institut national de santé publique du Québec, Montreal, Quebec, Canada.
- Department of Obstetrics and Gynecology, University of Montreal, Montreal, Quebec, Canada.
- University of Montreal Hospital Research Centre, Montreal, Quebec, Canada.
- Division of Dermatology, Montreal General Hospital, McGill University Health Centre, Montreal, Quebec, Canada.
Zitieren
APA
Li, K., Piguet, V., Croitoru, D., Wei, S. Q., Brousseau, É., O'Brien, E., & Auger, N. (2024). Hidradenitis Suppurativa and Maternal and Offspring Outcomes. JAMA Dermatology, 160(12), 1297. https://doi.org/10.1001/jamadermatol.2024.3584
Vancouver
Li K, Piguet V, Croitoru D, Wei SQ, Brousseau É, O'Brien E, et al. Hidradenitis Suppurativa and Maternal and Offspring Outcomes. JAMA Dermatology. 2024;160(12):1297. doi:10.1001/jamadermatol.2024.3584
BibTeX
@article{Li2024,
author = {Li, Kaiyang and Piguet, Vincent and Croitoru, David and Wei, Shu Qin and Brousseau, Émilie and O'Brien, Elizabeth and Auger, Nathalie},
title = {Hidradenitis Suppurativa and Maternal and Offspring Outcomes},
journal = {JAMA Dermatology},
year = {2024},
volume = {160},
number = {12},
pages = {1297},
doi = {10.1001/jamadermatol.2024.3584}
}
EUVIMED